VIVUS, Inc.  

(Public, NASDAQ:VVUS)   Watch this stock  
Find more results for VVUS
2.53
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.22 - 5.52
Open     -
Vol / Avg. 0.00/1.09M
Mkt cap 262.66M
P/E     -
Div/yield     -
EPS -0.80
Shares 103.82M
Beta 1.15
Inst. own 66%
Aug 5, 2015
Q2 2015 VIVUS Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 5, 2015
Q1 2015 VIVUS Inc Earnings Call - Webcast
May 5, 2015
Q1 2015 VIVUS Inc Earnings Release
Apr 14, 2015
VIVUS Inc at Needham Healthcare Conference
Feb 25, 2015
VIVUS Inc at RBC Healthcare Conference
Feb 24, 2015
Q4 2014 VIVUS Inc Earnings Call - Webcast
Feb 24, 2015
Q4 2014 Vivus Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -48.08% -72.38%
Operating margin -21.21% -44.41%
EBITD margin - -38.03%
Return on average assets -17.19% -20.69%
Return on average equity -82.06% -70.07%
Employees 94 -
CDP Score - -

Address

351 E Evelyn Ave
MOUNTAIN VIEW, CA 94041-1530
United States - Map
+1-650-9345200 (Phone)
+1-650-9345389 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vivus, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The Company's drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes. Its drug also includes STENDRA, or avanafil, is an oral PDE5 inhibitor, which the Company has licensed from Mitsubishi Tanabe Pharma Corporation (MTPC).

Officers and directors

Seth H. Z. Fischer Chief Executive Officer, Chief Commercial Officer, Director
Age: 58
Bio & Compensation  - Reuters
Svai S. Sanford Chief Financial Officer, Chief Accounting Officer
Age: 45
Bio & Compensation  - Reuters
John L. Slebir Esq. Senior Vice President - Business Development, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
Guy P. Marsh Vice President - U.S. Operations, General Manager
Age: 61
Bio & Compensation  - Reuters
Wesley W. Day Ph.D. Vice President - Clinical Development
Age: 50
Bio & Compensation  - Reuters
Alexander J. Denner Ph.D. Director
Bio & Compensation  - Reuters
David York Norton Director
Age: 63
Bio & Compensation  - Reuters
Herman Rosenman CPA Director
Age: 66
Bio & Compensation  - Reuters
Jorge Plutzky M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters